MC10 And The Shirley Ryan AbilityLab Initiate Research Collaboration To Develop Novel Solutions For Neurodegenerative Disease And Motion Disability Rehabilitation
CHICAGO & LEXINGTON, Mass.--(BUSINESS WIRE)--MC10, Inc., the company delivering wearable sensor systems for personalized health insights, and the Shirley Ryan AbilityLab (formerly Rehabilitation Institute of Chicago), the nationally recognized rehabilitation research hospital, today announced their collaboration around novel neurodegenerative and motion related disability therapy development.
The Shirley Ryan AbilityLab will execute clinical research studies using MC10’s BioStampRC® product, a wearable sensor system designed to seamlessly capture physiological data from across the body. MC10 and the hospital have partnered with the goal of determining how the BioStampRC System can be employed in clinical and home environments to advance the rehabilitation process.
“MC10’s technology has the potential to reshape rehabilitation. We look forward to developing new therapies and solutions with BioStampRC sensors, furthering our goal of improving treatment and recovery, and of advancing human ability,” stated David Zembower, Ph.D., Executive Director of Innovation and Clinical Research at the Shirley Ryan AbilityLab.
The research partnership will focus on identifying unmet clinical and therapeutic needs in the physical medicine and rehabilitation field. Initial target areas will include injuries that result in motion/biomechanics-related disabilities, especially stroke, traumatic brain injury, incomplete spinal cord injury, and various neurodegenerative diseases.
“MC10 is dedicated to improving healthcare with digital solutions. By collaborating with the Shirley Ryan AbilityLab, an institution committed to driving breakthroughs in human ability, we’re positioning our technology to make a real, positive impact in human health,” commented Scott Pomerantz, Chief Executive Officer of MC10.
The Shirley Ryan AbilityLab and MC10 plan for multiple publications and conference proceedings to share outcomes from their clinical study collaboration.
About Shirley Ryan AbilityLab
The Shirley Ryan AbilityLab, formerly the Rehabilitation Institute of Chicago (RIC), is the global leader in physical medicine and rehabilitation for adults and children with the most severe, complex conditions — from traumatic brain and spinal cord injury to stroke, amputation and cancer-related impairment. The Shirley Ryan AbilityLab expands and accelerates leadership in the field that began at RIC in 1953 — its care and research designated the “No. 1 Rehabilitation Hospital in America” by U.S. News & World Report every year since 1991. Upon opening in March 2017, the $550 million, 1.2-million-square-foot Shirley Ryan AbilityLab became the first-ever “translational” research hospital in which clinicians, scientists, innovators and technologists work together in the same space, surrounding patients, discovering new approaches and applying (or “translating”) research real time. Applied research focuses particularly in the areas of neuroscience, bionic medicine, musculoskeletal medicine and technology transfer. This unique model enables patients to have 24/7 access to the brightest minds, the latest research and the best opportunity for recovery. For more information, go to www.sralab.org.
About MC10, Inc.
MC10 is a private company, backed by a strong syndicate of financial and strategic investors, that is improving human health through digital healthcare solutions. The company combines its proprietary ultra-thin, flexible body-worn sensors with advanced analytics to unlock health insights from physiological data. MC10 has received widespread recognition for its revolutionary technology and was recently named in Fast Company’s Most Innovative Companies in 2016 as a leader in healthcare. MC10 is headquartered in Lexington, MA. Visit MC10 online at www.mc10inc.com.
MC10®, BioStampRC® and the MC10 logo are registered marks owned by MC10, Inc.